Chimeric Therapeutics (ASX:CHM) has received AU$4 million in non-dilutionary funding to develop its CHM CDH17, a cell therapy targeting cancer, according to a Thursday filing with the Australian bourse.
The funds, provided by an undisclosed US-based philanthropic family office, are non-refundable, with no further obligations, and no equity or intellectual property has been transferred, the filing said.
Chimeric clarified that the identity of the philanthropic family office does not have any material impact on the company's securities, the filing added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。